{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T01:46:57Z","timestamp":1726019217931},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000},"content-version":"vor","delay-in-days":10061,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[1979,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In a retrospective study, 58 patients with advanced colorectal carcinoma received one or more 5\u2010day infusions of 5\u2010FU at 20 mg\/kg per 24 hours followed by weekly IV 5\u2010FU at 15 mg\/kg. In 36 patients who received the infusion as first treatment (Group A), the response rate was 23% with a median duration of response of 8.0 months. No improvement in survival was noted. In 22 patients treated with the infusion after relapse on weekly 5\u2010FU (Group B), the response rate was 10.5% with a median duration of response of 4.5 months. Stable disease for 3\u20106 months was seen in 21%. Survival in Group B was improved when compared with a similar group of patients treated by weekly 5\u2010FU without infusion (Group C<jats:sub>B<\/jats:sub>), but statistical significance was not obtained. Twenty percent of patients were alive two years after relapsing on weekly 5\u2010FU when given the five\u2010day infusion of 5\u2010FU and re\u2010initiated on weekly 5\u2010FU.<\/jats:p><jats:p>Toxicity t o the five\u2010day infusion of 5\u2010FU was minimal. Three of 69 (4.3%) infusions were not completed because of toxicity.<\/jats:p><jats:p>A separate review of procarbazine indicated that it was minimally active in colorectal carcinoma.<\/jats:p><jats:p>Other patients with gastric and pancreatic carcinoma were reviewed but no statistical significance for 5\u2010FU infusion was seen for survival.<\/jats:p><jats:p>A five day continuous infusion of 5\u2010FU is recommended for colorectal cancer patients who relapse on weekly 5\u2010FU therapy. Further study of the infusion in combination with other chemotherapy is warranted.<\/jats:p>","DOI":"10.1002\/jso.2930110307","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T04:29:43Z","timestamp":1171945783000},"page":"227-238","source":"Crossref","is-referenced-by-count":8,"title":["Five\u2010day continuous infusion of 5\u2010fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma"],"prefix":"10.1002","volume":"11","author":[{"suffix":"JR.","given":"Herbert A.","family":"Hartman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Kessinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry M.","family":"Lemon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(74)80014-9"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jnci\/54.1.69","article-title":"Brief Communication: Therapy of Advanced Colorectal Cancer with a Combination of 5\u2010Fluorouracil, Methyl\u20101,3Cis(2\u2010chloroethyl)\u20101\u2010nitrosourea and Vincristine","volume":"54","author":"Moertel CG","year":"1975","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_4_2","first-page":"1597","article-title":"5\u2010Fluorouracil (5\u2010FU), Methyl CCNU, and Vincristine in the Treatment of Advanced Colorectal Cancer: Phase II Study Utilizing Weekly 5\u2010FU","volume":"60","author":"MacDonald JS","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197610)38:4<1468::AID-CNCR2820380403>3.0.CO;2-K"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197607)38:1<1::AID-CNCR2820380102>3.0.CO;2-S"},{"issue":"4","key":"e_1_2_1_7_2","first-page":"433","article-title":"Current Protocol Approaches in Large Bowel Cancer","volume":"3","author":"Carter SK","year":"1976","journal-title":"Seminars Oncol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197701)39:1<34::AID-CNCR2820390107>3.0.CO;2-2"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197507)36:1<123::AID-CNCR2820360108>3.0.CO;2-C"},{"key":"e_1_2_1_10_2","first-page":"331","article-title":"Survival of Patients with Advanced Gastrointestinal Cancer Treatment with 5\u2010Fluorouracil(5\u2010FU) Drip","volume":"18","author":"Grillo\u2010Lopez AJ","year":"1977","journal-title":"Proc Am Assoc Cancer Res ASCO"},{"key":"e_1_2_1_11_2","first-page":"271","article-title":"5\u2010FU Infusion with Mitomycin C vs. 5\u2010FU Infusion with Methyl CCNU in the Treatment of Advanced Colon Cancer. A Phase Ill Study. Proc Am Assoc","volume":"18","author":"Buroker T","year":"1977","journal-title":"Cancer Res ASCO"},{"key":"e_1_2_1_12_2","first-page":"1177","article-title":"5\u2010Day I.V. Infusion with 5\u2010Fluorouracil (5\u2010FU; NSC\u201019893) for Gastrointestinal Carcinoma after Failure on Weekly 5\u2010FU Therapy","volume":"59","author":"Hum GJ","year":"1975","journal-title":"Cancer Chemotherapy Res"},{"key":"e_1_2_1_13_2","first-page":"292","article-title":"High Dose Intravenous Infusions of 5\u2010Fluorouracil in Refractory Tumors \u2010 The Hi FU Regimen. Proc Am Assoc","volume":"18","author":"Spiers A","year":"1977","journal-title":"Cancer Res ASCO"},{"key":"e_1_2_1_14_2","first-page":"270","article-title":"Five\u2010Day Continuous Infusion of 5\u2010FU for Pancreatic Carcinoma","volume":"18","author":"Kessinger A","year":"1977","journal-title":"Proc Am Assoc Cancer Res ASCO"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.2930110307","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.2930110307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T04:57:33Z","timestamp":1699851453000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.2930110307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1979,1]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1979,1]]}},"alternative-id":["10.1002\/jso.2930110307"],"URL":"https:\/\/doi.org\/10.1002\/jso.2930110307","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[1979,1]]}}}